NRX Pharmaceuticals (STU:B1Q) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals ROE % Adjusted to Book Value?

NRX Pharmaceuticals's ROE % for the quarter that ended in Jun. 2024 was 0.00%. NRX Pharmaceuticals's PB Ratio for the quarter that ended in Jun. 2024 was N/A. NRX Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was N/A.

NRX Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for NRX Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals ROE % Adjusted to Book Value Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-30.97

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of NRX Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NRX Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's ROE % Adjusted to Book Value falls into.

NRX Pharmaceuticals ROE % Adjusted to Book Value Calculation

NRX Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

NRX Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

NRX Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals Headlines

No Headlines